Family history of Alzheimer's disease alters cognition and is modified by medical and genetic factors

  1. Joshua S Talboom
  2. Asta K Håberg
  3. Matthew D De Both
  4. Marcus A Naymik
  5. Isabelle Schrauwen
  6. Candace R Lewis
  7. Stacy F Bertinelli
  8. Callie Hammersland
  9. Mason A Fritz
  10. Amanda J Myers
  11. Meredith Hay
  12. Carol A Barnes
  13. Elizabeth Glisky
  14. Lee Ryan
  15. Matthew J Huentelman  Is a corresponding author
  1. The Translational Genomics Research Institute, United States
  2. Norwegian University of Science and Technology, Norway
  3. University of Miami, United States
  4. Arizona Alzheimer's Consortium, United States

Abstract

In humans, a first-degree family history of dementia (FH) is a well-documented risk factor for Alzheimer's disease (AD); however, the influence of FH on cognition across the lifespan is poorly understood. To address this issue, we developed an internet-based paired-associates learning (PAL) task and tested 59,571 participants between the ages of 18-85. FH was associated with lower PAL performance in both sexes under 65 years old. Modifiers of this effect of FH on PAL performance included age, sex, education, and diabetes. The Apolipoprotein E ε4 allele was also associated with lower PAL scores in FH positive individuals. Here we show, FH is associated with reduced PAL performance four decades before the typical onset of AD; additionally, several heritable and non-heritable modifiers of this effect were identified.

Data availability

The data that support the findings of this study are freely available at Dryad (https://datadryad.org) doi:10.5061/dryad.2867k2m.

The following data sets were generated

Article and author information

Author details

  1. Joshua S Talboom

    The Translational Genomics Research Institute, Phoenix, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4327-4103
  2. Asta K Håberg

    Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology, Trondheim, Norway
    Competing interests
    The authors declare that no competing interests exist.
  3. Matthew D De Both

    The Translational Genomics Research Institute, Phoenix, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Marcus A Naymik

    The Translational Genomics Research Institute, Phoenix, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Isabelle Schrauwen

    The Translational Genomics Research Institute, Phoenix, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Candace R Lewis

    The Translational Genomics Research Institute, Phoenix, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Stacy F Bertinelli

    The Translational Genomics Research Institute, Phoenix, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Callie Hammersland

    The Translational Genomics Research Institute, Phoenix, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Mason A Fritz

    The Translational Genomics Research Institute, Phoenix, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Amanda J Myers

    Department of Psychiatry and Behavioral Sciences, University of Miami, Miami, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Meredith Hay

    Arizona Alzheimer's Consortium, Phoenix, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. Carol A Barnes

    Arizona Alzheimer's Consortium, Phoenix, United States
    Competing interests
    The authors declare that no competing interests exist.
  13. Elizabeth Glisky

    Arizona Alzheimer's Consortium, Phoenix, United States
    Competing interests
    The authors declare that no competing interests exist.
  14. Lee Ryan

    Arizona Alzheimer's Consortium, Phoenix, United States
    Competing interests
    The authors declare that no competing interests exist.
  15. Matthew J Huentelman

    The Translational Genomics Research Institute, Phoenix, United States
    For correspondence
    mhuentelman@tgen.org
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7390-9918

Funding

Mueller Family Charitable Trust

  • Matthew J Huentelman

Arizona DHS in support of the Arizona Alzheimer's Consortium

  • Matthew J Huentelman

Flinn Foundation

  • Matthew J Huentelman

National Institutes of Health (R01- AG041232)

  • Amanda J Myers

National Institutes of Health (R01-AG049465-05)

  • Carol A Barnes

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: For all participants, informed consent, and consent to publish was obtained before study participation. This protocol and consent were approved by the Western Institutional Review Board (WIRB, protocol #20111988).

Reviewing Editor

  1. Muireann Irish, University of Sydney, Australia

Version history

  1. Received: February 18, 2019
  2. Accepted: June 13, 2019
  3. Accepted Manuscript published: June 18, 2019 (version 1)
  4. Version of Record published: July 9, 2019 (version 2)

Copyright

© 2019, Talboom et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 7,449
    Page views
  • 578
    Downloads
  • 18
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Joshua S Talboom
  2. Asta K Håberg
  3. Matthew D De Both
  4. Marcus A Naymik
  5. Isabelle Schrauwen
  6. Candace R Lewis
  7. Stacy F Bertinelli
  8. Callie Hammersland
  9. Mason A Fritz
  10. Amanda J Myers
  11. Meredith Hay
  12. Carol A Barnes
  13. Elizabeth Glisky
  14. Lee Ryan
  15. Matthew J Huentelman
(2019)
Family history of Alzheimer's disease alters cognition and is modified by medical and genetic factors
eLife 8:e46179.
https://doi.org/10.7554/eLife.46179

Further reading

    1. Medicine
    Chandramohan Chitraju, Alexander W Fischer ... Robert V Farese Jr
    Research Article

    Triglycerides (TGs) in adipocytes provide the major stores of metabolic energy in the body. Optimal amounts of TG stores are desirable as insufficient capacity to store TG, as in lipodystrophy, or exceeding the capacity for storage, as in obesity, results in metabolic disease. We hypothesized that mice lacking TG storage in adipocytes would result in excess TG storage in cell types other than adipocytes and severe lipotoxicity accompanied by metabolic disease. To test this hypothesis, we selectively deleted both TG synthesis enzymes, DGAT1 and DGAT2, in adipocytes (ADGAT DKO mice). As expected with depleted energy stores, ADGAT DKO mice did not tolerate fasting well and, with prolonged fasting, entered torpor. However, ADGAT DKO mice were unexpectedly otherwise metabolically healthy and did not accumulate TGs ectopically or develop associated metabolic perturbations, even when fed a high-fat diet. The favorable metabolic phenotype resulted from activation of energy expenditure, in part via BAT (brown adipose tissue) activation and beiging of white adipose tissue. Thus, the ADGAT DKO mice provide a fascinating new model to study the coupling of metabolic energy storage to energy expenditure.

    1. Medicine
    2. Stem Cells and Regenerative Medicine
    Thiruma V Arumugam, Asfa Alli-Shaik ... Jayantha Gunaratne
    Research Article

    Intermittent fasting (IF) has been shown to reduce cardiovascular risk factors in both animals and humans, and can protect the heart against ischemic injury in models of myocardial infarction. However, the underlying molecular mechanisms behind these effects remain unclear. To shed light on the molecular and cellular adaptations of the heart to IF, we conducted comprehensive system-wide analyses of the proteome, phosphoproteome, and transcriptome, followed by functional analysis. Using advanced mass spectrometry, we profiled the proteome and phosphoproteome of heart tissues obtained from mice that were maintained on daily 12- or 16 hr fasting, every-other-day fasting, or ad libitum control feeding regimens for 6 months. We also performed RNA sequencing to evaluate whether the observed molecular responses to IF occur at the transcriptional or post-transcriptional levels. Our analyses revealed that IF significantly affected pathways that regulate cyclic GMP signaling, lipid and amino acid metabolism, cell adhesion, cell death, and inflammation. Furthermore, we found that the impact of IF on different metabolic processes varied depending on the length of the fasting regimen. Short IF regimens showed a higher correlation of pathway alteration, while longer IF regimens had an inverse correlation of metabolic processes such as fatty acid oxidation and immune processes. Additionally, functional echocardiographic analyses demonstrated that IF enhances stress-induced cardiac performance. Our systematic multi-omics study provides a molecular framework for understanding how IF impacts the heart’s function and its vulnerability to injury and disease.